proton
channel
influenza
viru
target
antiinfluenza
drug
amantadin
rimantadin
effect
drug
dramat
limit
rapid
spread
drug
resist
mutat
mainli
site
pore
channel
despit
progress
design
inhibitor
current
drug
target
mutat
channel
clinic
trial
progress
develop
new
drug
hamper
lack
robust
assay
suffici
throughput
discoveri
new
activ
chemotyp
among
chemic
librari
suffici
sensit
provid
sar
data
essenti
improv
develop
drug
studi
adapt
yeast
growth
restor
assay
express
channel
inhibit
yeast
growth
exposur
channel
inhibitor
restor
growth
robust
sensit
highthroughput
screen
channel
inhibitor
screen
pure
chemic
semipurifi
fraction
natur
extract
identifi
activ
compound
compris
amantadin
rimantadin
relat
adamantan
nonadamantan
nonadamantan
hexamethylen
amilorid
triazin
deriv
repres
new
inhibitori
chemotyp
also
show
antivir
activ
plaqu
reduct
assay
particular
interest
fact
triazin
deriv
suffici
potent
detect
inhibitor
tradit
two
electrod
voltag
clamp
assay
channel
activ
discoveri
yeast
assay
led
test
analogu
one
potent
amantadin
influenza
virus
highli
infecti
pathogen
respons
season
epidem
pandem
worldwid
season
epidem
result
million
case
sever
ill
death
yearli
pandem
spanish
flu
asian
flu
hong
kong
flu
swine
flu
result
million
death
vaccin
primari
strategi
prevent
antivir
agent
need
manag
season
influenza
vulner
patient
essenti
gener
appropri
vaccin
rapid
enough
new
pandem
four
drug
current
approv
usa
influenza
treatment
viral
neuraminidas
inhibitor
oseltamivir
zanamivir
viral
proton
channel
inhibitor
amantadin
methyl
deriv
rimantadin
agent
amantadin
rimantadin
oseltamivir
oral
administ
strain
resist
inhibitor
predomin
resist
oseltamivir
increasingli
encount
emerg
strain
resist
approv
drug
distinct
possibl
could
particularli
seriou
repercuss
event
new
pandem
progress
made
develop
new
neuraminidas
inhibitor
less
progress
proton
channel
inhibitor
proton
channel
requir
viru
replic
matur
viru
taken
host
cell
endocytosi
low
ph
endosom
activ
channel
allow
proton
flux
endosom
viral
interior
acidif
dissoci
viral
rna
bound
matrix
protein
permit
releas
viral
genet
materi
cytoplasm
replic
protein
also
equilibr
ph
gradient
golgi
lumen
cytoplasm
prevent
prematur
conform
chang
hemagglutinin
viral
matur
homotetram
chain
consist
short
unstructur
extracellular
ntermin
domain
residu
import
incorpor
virion
singl
transmembran
domain
necessari
suffici
tetramer
proton
conduct
drug
bind
amphiphil
membraneassoci
ahelix
residu
import
viral
bud
scission
unstructur
ctermin
cytoplasm
tail
residu
interact
matrix
protein
amantadin
bind
transmembran
region
charg
amino
group
mimick
hydronium
proton
conduct
rate
channel
match
ph
sensit
hemagglutinin
larg
number
amantadineresist
mutat
identifi
vitro
three
identifi
transmiss
virus
singl
amino
acid
substitut
channel
develop
inhibitor
activ
amantadineresist
channel
highli
desir
challeng
produc
assay
membran
protein
nativelik
condit
method
assay
ion
channel
activ
labor
intens
technic
demand
therefor
unsuit
highthroughput
screen
chemic
librari
krystal
et
al
show
channel
gene
express
yeast
saccharomyc
cerevisia
protonselect
channel
form
disrupt
electrochem
potenti
across
yeast
membran
inhibit
yeast
growth
compound
block
channel
activ
abl
restor
growth
principl
also
appli
use
e
coli
implement
high
throughput
screen
studi
develop
yeast
growth
restor
assay
highthroughput
screen
inhibitor
channel
use
discov
addit
analog
known
channel
inhibitor
also
amilorid
deriv
substitut
triazin
repres
chemotyp
previous
unrecogn
channel
inhibitor
provid
new
start
point
influenza
drug
develop
restor
assay
detect
inhibitor
channel
cerevisia
strain
gener
contain
multicopi
plasmid
express
wildtyp
gene
udorn
strain
influenza
control
induc
promot
design
wt
respect
empti
plasmid
growth
four
strain
monitor
time
turbidimetri
follow
induct
promot
galactos
express
wt
consider
slow
yeast
growth
growth
control
strain
h
fig
b
express
amantadineresist
reduc
yeast
growth
control
strain
express
reduc
growth
control
fig
amantadin
use
test
whether
observ
growth
inhibit
caus
proton
channel
activ
growth
yeast
strain
contain
empti
plasmid
affect
amantadin
mm
fig
contrast
amantadin
consider
increas
growth
strain
express
wt
control
without
amantadin
control
mm
amantadin
control
mm
mm
fig
amantadin
increas
growth
strain
fig
expect
sinc
mutat
channel
amantadineresist
test
whether
growth
inhibit
amantadineresist
mutant
also
depend
proton
channel
activ
use
spiroadamantan
amin
fig
compound
inhibit
mutant
channel
well
wt
channel
two
electrod
voltag
clamp
tvec
assay
channel
conduct
ic
mm
respect
also
inhibit
replic
recombin
virus
bear
mutat
plaqu
reduct
assay
discuss
previous
assay
conduct
short
time
scale
min
acidif
due
limit
stabil
oocyt
low
ph
prior
establish
equilibrium
ic
valu
obtain
tevc
assay
therefor
one
two
order
magnitud
larger
cellular
assay
conduct
longer
time
scale
accord
expect
spiroadamantan
amin
clearli
increas
growth
strain
mm
ec
mm
fig
also
restor
growth
wt
strain
concentr
rang
fig
interestingli
spiroadamantan
amin
potent
wt
strain
ec
mm
fig
amantadin
ec
mm
result
drugsensit
drugresist
mutant
mutantselect
inhibitor
show
yeast
growth
restor
result
inhibit
proton
channel
activ
moreov
abil
low
concentr
inhibitor
significantli
restor
growth
indic
potenti
assay
develop
sensit
screen
inhibitor
determin
whether
assay
could
use
discov
new
inhibitor
simpl
benchtop
plate
assay
develop
see
materi
method
assay
show
good
discrimina
tion
growth
strain
express
wt
empti
plasmid
fig
accept
z
factor
use
assay
pilot
screen
commerci
avail
pure
chemic
prestwick
biomol
sigma
lopac
microsourc
spectrum
maybridg
hitfind
chembridg
diverset
repres
exampl
screen
batch
compound
correspond
control
well
test
day
shown
fig
mani
compound
inhibit
yeast
growth
one
show
substanti
growth
restor
compound
rimantadin
deriv
effect
growth
yeast
strain
carri
empti
plasmid
increas
growth
wt
strain
concentrationdepend
manner
ec
mm
fig
overal
pilot
screen
identifi
activ
compound
well
amantadin
rimantadin
fig
encourag
find
sought
increas
capac
autom
assay
enabl
highthroughput
screen
similar
assay
use
plate
autom
liquid
handl
plate
read
establish
assay
yeast
express
wt
treat
amantadin
use
establish
assay
z
factor
averag
assay
use
screen
pure
compound
chembridg
yield
addit
activ
compound
fig
enabl
discoveri
structur
novel
compound
also
carri
screen
semipurifi
fraction
natur
bank
collect
natur
product
extract
fraction
typic
contain
sever
compound
test
dilut
expect
result
individu
compound
present
mm
assum
mw
fraction
show
level
growth
restor
nevertheless
fraction
show
increas
growth
mm
amantadin
caus
growth
increas
retest
none
show
activ
yeast
growth
restor
screen
identifi
activ
compound
includ
amantadin
rimantadin
adamantan
nonadamantan
activ
compound
confirm
concentr
curv
name
structur
ec
valu
shown
fig
ec
activ
compound
rang
mm
four
adamantan
two
nonadamantan
ec
valu
mm
compound
except
weak
inhibitor
bipartit
structur
previou
inhibitor
includ
hydrophob
scaffold
eg
adamantan
bicycloheptan
cyclooctan
polar
head
group
examin
activ
adamantan
fig
show
wide
varieti
substitut
toler
either
posit
adamantan
includ
substitut
benzyl
fivememb
heterocycl
sixmemb
heterocycl
substitut
compound
primari
secondari
amin
like
proton
ph
assay
medium
ph
find
consist
earlier
studi
suggest
ammonium
serv
mimic
hydronium
ion
channel
addit
compound
bear
basic
heterocycl
acylguanidin
tertiari
amin
might
also
proton
near
neutral
slightli
acid
ph
remain
compound
contain
neutral
polar
group
particularli
cyclic
acycl
thiourea
sulfonamid
seen
previous
report
inhibitor
compound
select
test
tevc
assay
found
inhibit
wt
channel
activ
mm
fig
correl
yeast
screen
result
ec
mm
fig
among
activ
compound
contain
adamantan
moieti
fig
bicycl
compound
deriv
pinen
camphor
bicycloheptan
shown
previous
inhibitor
support
statement
wt
channel
abl
accommod
hydrophob
molecul
cage
shape
adamantan
pyrrolesubstitut
cyclooctylamin
activ
poor
ec
mm
cyclooctylamin
found
shroeder
group
block
channel
proton
flux
liposom
assay
bind
affin
later
determin
weaker
amantadin
togeth
result
show
wt
channel
abl
accommod
compound
divers
structur
significantli
two
activ
compound
hexamethylen
amilorid
triazin
ec
mm
respect
report
previous
inhibitor
determin
whether
restor
yeast
growth
compound
truli
result
channel
inhibit
purchas
synthes
sever
analog
test
tevc
assay
directli
measur
proton
channel
conduct
hexamethylen
amilorid
highli
activ
wt
channel
conduct
inhibit
mm
activ
amantadin
fig
three
close
structur
analog
also
test
show
moder
inhibit
tabl
howev
clear
structureact
relationship
observ
seri
amilorid
analog
hydrophob
molecul
potent
inhibit
anticip
base
earlier
sar
result
activ
compound
triazin
activ
tevc
assay
mm
tabl
twelv
close
relat
structur
analog
compound
test
tvec
assay
interestingli
two
compound
hydrophob
scaffold
seven
carbon
atom
activ
fig
other
essenti
inact
assay
inhibit
mm
tabl
activ
compound
test
yeast
growth
restor
assay
show
ec
valu
mm
mm
respect
compar
ec
mm
triazin
given
good
correspond
inhibit
mm
tevc
assay
potenc
yeast
assay
compound
identifi
fact
tevc
assay
requir
much
higher
inhibitor
concentr
yeast
assay
show
activ
surmis
triazin
fals
posit
yeast
assay
rather
true
inhibitor
suffici
potent
detect
tvec
assay
taken
togeth
result
point
import
contribut
hydrophob
scaffold
high
activ
inhibitor
compound
wt
rather
polar
headgroup
explain
wide
varieti
polar
headgroup
toler
given
high
preval
amantadineresist
mutat
season
flu
strain
interest
determin
whether
compound
found
activ
wt
also
show
activ
toward
mutant
channel
compound
test
two
mutant
yeast
assay
compound
show
signific
activ
mutant
ec
mm
inact
compound
inact
compound
also
test
mm
mutant
channel
tevc
assay
found
inact
fig
tabl
two
potent
adamantan
two
nonadamantan
test
inhibit
influenza
replic
mdck
plaqu
reduct
assay
amantadin
posit
control
four
compound
complet
inhibit
plaqu
format
mm
fig
mm
compound
almost
complet
inhibit
plaqu
format
compar
mm
amantadin
compound
show
moder
inhibit
compound
nearli
effect
fig
potenc
antivir
effect
consist
low
ec
yeast
growth
restor
assay
mm
mm
mm
respect
compar
ec
mm
amantadin
good
potenc
compound
agre
tevc
assay
result
show
inhibit
mm
amantadin
mm
hexamethyleneamilorid
less
potent
yeast
assay
ec
mm
also
less
potent
plaqu
reduct
assay
four
compound
also
test
cytotox
toward
uninfect
mdck
cell
compound
show
low
cytotox
indic
good
activ
window
hexamethyleneamilorid
cytotox
cc
mm
fig
indic
less
favor
activ
window
overal
result
demonstr
yeast
growth
restor
assay
identifi
inhibitor
antivir
activ
progress
find
new
inhibitor
target
drug
resist
channel
slow
recent
advanc
understand
structur
dynam
properti
channel
lipid
bilay
environ
interact
amantadin
channel
spur
structurebas
drug
design
virtual
screen
effort
sever
new
inhibitor
describ
last
year
mani
close
resembl
amantadin
howev
inhibitor
target
drug
resist
mutant
report
notabl
except
spiroadamantan
amin
shown
fig
activ
wt
robust
sensit
highthroughput
screen
assay
would
enabl
sampl
expand
chemic
divers
repertoir
guid
sar
studi
studi
modifi
assay
describ
krystal
et
al
optim
highthroughput
screen
notabl
express
yeast
strain
defect
drug
efflux
system
simplifi
autom
assay
condit
result
growth
restor
assay
robust
highli
sensit
quantit
costeffect
technic
simpl
found
yeast
growth
inhibit
greatest
wt
give
rise
good
z
factor
screen
success
drug
inhibit
wt
well
amantadineresist
mutat
form
use
wt
primari
screen
follow
test
activ
compound
mutant
secondari
assay
screen
pure
chemic
semipurifi
fraction
natur
extract
identifi
activ
compound
hit
rate
lower
typic
encount
screen
target
assay
show
high
select
channel
inhibitor
test
activ
compound
reveal
fals
posit
posit
readout
cellbas
assay
high
select
impart
larg
requir
activ
compound
inhibit
target
hamper
cell
growth
effect
elimin
mani
nonselect
activ
chemic
howev
sinc
observ
higher
hit
rate
yeast
growth
restor
assay
target
low
hit
rate
pauciti
chemic
class
identifi
indic
easili
inhibit
druglik
synthet
chemic
assembl
commerci
avail
librari
natur
product
known
encompass
much
wider
rang
biolog
relev
chemic
space
surpris
largescal
screen
semipurifi
fraction
obtain
natur
extract
yield
singl
hit
believ
due
technic
factor
test
fraction
low
concentr
reveal
activ
rather
think
indic
channel
select
inhibit
pharmacophor
challeng
target
drug
develop
nonetheless
screen
identifi
two
compound
novel
structur
channel
inhibitor
hexamethylen
amilorid
triazin
test
tevc
assay
confirm
hexamethylen
amilorid
inhibit
channel
subsequ
sar
evalu
amilorid
analog
show
hydrophob
play
critic
role
channel
inhibit
hexamethylen
amilorid
known
inhibitor
mammalian
na
h
exchang
also
activ
hcv
proton
channel
vpu
ion
channel
sar
coronaviru
envelop
protein
ion
channel
activ
hexamethylen
amilorid
inhibit
mammalian
na
h
exchang
appar
k
mm
potent
inhibit
yeast
assay
ec
mm
therefor
appear
good
drug
candid
deriv
describ
inhibitor
influenza
b
viru
replic
uncharacter
mechan
action
triazin
describ
consider
differ
previous
link
inhibit
ion
channel
triazin
complet
inhibit
influenza
replic
mm
toxic
mdck
cell
cc
mm
compound
may
good
start
point
drug
discoveri
high
sensit
yeastbas
assay
also
reveal
spiroadamantan
amin
shown
fig
highli
potent
amantadineresist
mutant
report
potent
inhibitor
wt
channel
amantadin
rimantadin
may
therefor
candid
drug
develop
togeth
result
demonstr
valu
yeast
growth
restor
assay
high
throughput
screen
inhibitor
discoveri
antiinfluenza
agent
multicopi
express
plasmid
yeast
strain
assay
measur
yeast
growth
use
studi
describ
detail
previou
public
code
sequenc
udorn
wt
gene
introduc
downstream
promot
pcr
amplif
follow
recombin
clone
yeast
plasmid
rescu
yeast
strain
code
sequenc
sequenceverifi
yeast
strain
propag
synthet
complet
sc
medium
ph
lack
leucin
contain
glucos
repress
gene
express
measur
growth
express
condit
yeast
harvest
centrifug
pellet
wash
water
remov
trace
glucos
suspend
liquid
sc
medium
ph
lack
leucin
contain
galactos
ml
sampl
distribut
plate
incub
humidifi
chamber
without
agit
measur
micropl
reader
differ
time
suspend
cell
gentl
thorough
vortex
wt
yeast
grown
suspend
liquid
sc
medium
without
leucin
galactos
distribut
ml
per
well
steril
transpar
plate
use
dispens
pipetor
screen
chemic
transfer
mm
stock
solut
dmso
yeast
plate
final
concentr
mm
use
biorobot
robot
equip
mm
diamet
tool
plate
incub
humidifi
incub
h
cell
suspend
vortex
measur
percentag
growth
restor
calcul
describ
chemic
show
growth
restor
retest
triplic
differ
concentr
wt
empti
plasmid
strain
confirm
activ
determin
ec
plate
assay
adapt
format
follow
ml
sc
medium
lack
leucin
contain
galactos
distribut
well
corn
clear
polystyren
plate
use
matrix
wellmat
micropl
dispens
screen
chemic
extract
ad
use
matrix
platem
plu
autom
liquid
handl
system
equip
mm
diamet
tool
transfer
nl
ml
yeast
medium
ad
use
matrix
wellmat
dispens
plate
incub
humidifi
fisher
isotemp
incub
h
measur
without
shake
use
biotek
powerwav
plate
reader
integr
biotek
biostack
plate
stack
system
plate
assay
batch
plate
plate
contain
control
well
expos
drug
control
well
mm
amantadin
dispens
use
matrix
wellmat
compound
test
via
twoelectrod
patch
clamp
assay
use
xenopu
laevi
oocyt
microinject
rna
express
wt
gene
compound
list
fig
tabl
obtain
either
commerci
sourc
use
without
purif
synthes
accord
literatur
procedur
follow
compound
order
sigmaaldrich
cat
fig
amin
mmol
mix
formaldehyd
mmol
dioxan
ml
isothiourea
mmol
subsequ
ad
mixtur
heat
clear
solut
form
allow
stir
room
temperatur
overnight
mixtur
extract
dichloromethan
satur
nahco
solut
organ
phase
combin
dri
mgso
filter
solvent
remov
reduc
pressur
crude
product
purifi
silica
gel
flash
column
chromatographi
gradient
ch
ohdichloromethan
synthes
compound
character
hnmr
ms
select
compound
also
character
cnmr
methylthio
cyclohexylmethyl
ethylthio
tabl
activ
hexamethylen
amilorid
triazin
analog
tevc
assay
author
contribut
